Compugen, Cornell University, US National Science Foundation, Molecular Devices, Axon, Southern California Genotyping Consortium, Qiagen, Affymetrix, Perlegen Sciences, Institut Gustave-Roussy | GenomeWeb

Compugen Establishes Small-Molecule, Drug Discovery Subsidiary

Tel Aviv, Israel-based Compugen last week announced Keddem Bioscience Limited, a small-molecule drug discovery company that formerly was the company’s chemistry division. The subsidiary’s offices and labs are located in Ashkelon, Israel.

The company said that its Keddem subsidiary would approach drug discovery by proposing the creation of a comprehensive, yet relatively small set of screening molecules (less than 100,000), and a suite of algorithms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.